NRG Oncology trial supports radiotherapy and cisplatin should remain the standard of care for p16+ oropharyngeal cancer
The NRG Oncology NRG-HN005 phase II/III clinical trial did not meet the non-inferiority criteria to proceed to the phase III portion of the study. The phase II portion of the NRG-HN005 evaluated two experimental treatment arms against a control arm for …